Short-term effects of montelukast in stable patients with moderate to severe COPD

Simple item page
dc.contributor.authorCelik P.
dc.contributor.authorSakar A.
dc.contributor.authorHavlucu Y.
dc.contributor.authorYuksel H.
dc.contributor.authorTurkdogan P.
dc.contributor.authorYorgancioglu A.
dc.date.accessioned2024-07-22T08:24:06Z
dc.date.available2024-07-22T08:24:06Z
dc.date.issued2005
dc.description.abstractThis study aims to investigate the possibility of additional value of leukotriene receptor antagonist (LTA) on dyspnea score, arterial blood gases (ABG), pulmonary function tests (PFTs), and quality of life (St. George QoL) in chronic obstructive pulmonary disease (COPD) patients. In this randomized, prospective, single-blind, and controlled study, 117 non-reversible COPD patients defined by global initiative for chronic obstructive lung disease (GOLD) criteria were randomized to receive ipratropium bromide, formoterol and montelukast (n:58, montelukast group) or ipratropium bromide and formoterol (n:59, control group) after a 2-week run-in period. There was no significant demographic difference between the two groups (P > 0.05). Baseline ABG, PFT, visual analoque scores (VAS), and QoL scores were obtained and at first month and second month, PFT, VAS, and QoL scores were repeated and ABG was obtained at second month and the values were compared with baseline values. As the result of the comparision, there was significant increase in vital capacity, FVC, FEV1, VAS, and PaO2 parameters (P < 0.05), and a significant decrease in the QoL scores (P < 0.05) in the montelukast group. These parameters did not show any difference in the control group (P > 0.05). Sputum samples that could be obtained in 24 of the COPD patients were evaluated and in the montelukast group, there was a decrease in neutrophilic activity after treatment (n:13) (P : 0.059). These results suggest that LTA that is used additionally in routine treatment protocol can produce additive improvement on PFT, dyspnea score and especially QoL in patients with stable COPD and for these reasons, LTA may be taken into account when there is need for an additional anti-inflammatory treatment in COPD patients. © 2004 Elsevier Ltd. All rights reserved.
dc.identifier.DOI-ID10.1016/j.rmed.2004.09.008
dc.identifier.issn09546111
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19831
dc.language.isoEnglish
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAcetates
dc.subjectAged
dc.subjectDyspnea
dc.subjectFemale
dc.subjectHumans
dc.subjectLeukotriene Antagonists
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeutrophils
dc.subjectProspective Studies
dc.subjectPulmonary Disease, Chronic Obstructive
dc.subjectQuality of Life
dc.subjectQuinolines
dc.subjectRespiratory Function Tests
dc.subjectSingle-Blind Method
dc.subjectSputum
dc.subjectformoterol
dc.subjectipratropium bromide
dc.subjectmontelukast
dc.subjectadult
dc.subjectaged
dc.subjectarterial gas
dc.subjectarterial oxygen tension
dc.subjectarticle
dc.subjectchronic obstructive lung disease
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdemography
dc.subjectdisease severity
dc.subjectdrug potentiation
dc.subjectdyspnea
dc.subjectfemale
dc.subjectforced expiratory volume
dc.subjecthuman
dc.subjectlung function test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectneutrophil
dc.subjectpriority journal
dc.subjectprospective study
dc.subjectquality of life
dc.subjectrandomized controlled trial
dc.subjectsingle blind procedure
dc.subjectsputum analysis
dc.subjectvisual analog scale
dc.subjectvital capacity
dc.titleShort-term effects of montelukast in stable patients with moderate to severe COPD
dc.typeArticle

Files

Collections

Scopus Koleksiyonu